{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:05:59Z","timestamp":1789031159653,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004913","name":"Universit\u00e0 degli Studi di Palermo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in type 2 diabetes mellitus (T2DM), but the burden of steatosis and fibrosis and their associated factors remain incompletely defined. We assessed the prevalence, severity, and factors associated with of MASLD in a real-world cohort of patients with T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study, 219 consecutive outpatients with T2DM underwent anthropometric laboratory, ultrasonographic and shear-wave elastographic assessment. MASLD was defined by the multisociety Delphi consensus. Independent associations were evaluated using multivariable logistic regression, with waist circumference as the primary adiposity measure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MASLD was diagnosed in 75.3% of participants. Severe steatosis (S3) was present in 11.9%, clinically significant fibrosis (F\u2009\u2265\u20092) in 7.3%, and advanced fibrosis (F\u2009\u2265\u20093) in 5.5%. Male sex (OR 2.49, 95% CI 1.26\u20134.94) and waist circumference (OR 1.04 per cm, 95% CI 1.01\u20131.07) were independently associated with MASLD. Severe steatosis was independently associated with male sex and waist circumference. MASLD prevalence increased across waist circumference quartiles (trend\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), while the adjusted odds plateaued in the upper half, paralleled by a higher prevalence of severe steatosis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), whereas fibrosis was not associated with abdominal adiposity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.65). HbA1c and diabetes duration did not differ between groups in univariable comparisons, and age was not associated with MASLD in the multivariable models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MASLD is highly prevalent in T2DM and is independently associated with male sex and central adiposity. Abdominal adiposity identifies steatosis risk in a graded manner but does not discriminate fibrosis, supporting adiposity- and sex-informed hepatic phenotyping in patients with T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00592-026-02791-5","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:06:37Z","timestamp":1789027597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MASLD in type 2 diabetes: steatosis\u2013fibrosis burden and metabolic determinants in a real-world cohort"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-1374","authenticated-orcid":false,"given":"Salvatore","family":"Corrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3236-3340","authenticated-orcid":false,"given":"Salvatore","family":"Scibetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Bongiorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Lopriore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2702-5551","authenticated-orcid":false,"given":"Luigi","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Local Outpatient Registry Investigators (LOR-i)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"6","key":"2791_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79(6):1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"issue":"7","key":"2791_CR2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J et al (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(7):1999\u20132014e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"issue":"2","key":"2791_CR3","doi-asserted-by":"publisher","first-page":"103702","DOI":"10.1016\/j.numecd.2024.07.019","volume":"35","author":"S Corrao","year":"2025","unstructured":"Corrao S, Calvo L, Gran\u00e0 W et al (2025) Metabolic dysfunction-associated steatotic liver disease: a pathophysiology and clinical framework to face the present and the future. Nutr Metab Cardiovasc Dis 35(2):103702. https:\/\/doi.org\/10.1016\/j.numecd.2024.07.019","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"17","key":"2791_CR4","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J et al (2021) Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 385(17):1559\u20131569. https:\/\/doi.org\/10.1056\/NEJMoa2029349","journal-title":"N Engl J Med"},{"issue":"10","key":"2791_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK et al (2024) The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 22(10):1999\u20132010 .e8. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2791_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","volume":"44","author":"R Lomonaco","year":"2021","unstructured":"Lomonaco R, Godinez Leiva E, Bril F et al (2021) Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care 44(2):399\u2013406. https:\/\/doi.org\/10.2337\/dc20-1997","journal-title":"Diabetes Care"},{"key":"2791_CR7","unstructured":"American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes\u20142026. Diabetes Care (2026) ;49(Suppl. 1)"},{"issue":"3","key":"2791_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL) (2024) EASD, EASO. EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"2791_CR9","doi-asserted-by":"publisher","first-page":"103926","DOI":"10.1016\/j.numecd.2025.103926","volume":"35","author":"S Corrao","year":"2025","unstructured":"Corrao S, Scibetta S, Scardina S et al (2025) Prevalence and association of metabolism-associated steatotic liver disease across age groups and gender. Nutr Metab Cardiovasc Dis 35:103926. https:\/\/doi.org\/10.1016\/j.numecd.2025.103926","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"2791_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S et al (2019) Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 70(4):1457\u20131469. https:\/\/doi.org\/10.1002\/hep.30626","journal-title":"Hepatology"},{"issue":"8","key":"2791_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/liv.14943","volume":"41","author":"P Burra","year":"2021","unstructured":"Burra P, Bizzaro D, Gonta A et al (2021) Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 41(8):1713\u20131733. https:\/\/doi.org\/10.1111\/liv.14943","journal-title":"Liver Int"},{"key":"2791_CR12","doi-asserted-by":"publisher","first-page":"889923","DOI":"10.3389\/fendo.2022.889923","volume":"13","author":"BM Steiner","year":"2022","unstructured":"Steiner BM, Berry DC (2022) The regulation of adipose tissue health by estrogens. Front Endocrinol 13:889923. https:\/\/doi.org\/10.3389\/fendo.2022.889923","journal-title":"Front Endocrinol"},{"issue":"11","key":"2791_CR13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41591-019-0643-8","volume":"25","author":"E Gerdts","year":"2019","unstructured":"Gerdts E, Regitz-Zagrosek V (2019) Sex differences in cardiometabolic disorders. Nat Med 25(11):1657\u20131666. https:\/\/doi.org\/10.1038\/s41591-019-0643-8","journal-title":"Nat Med"},{"issue":"40","key":"2791_CR14","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3748\/wjg.v25.i40.6053","volume":"25","author":"G Ferraioli","year":"2019","unstructured":"Ferraioli G, Soares Monteiro LB (2019) Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol 25(40):6053\u20136062. https:\/\/doi.org\/10.3748\/wjg.v25.i40.6053","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2791_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/osp4.453","volume":"6","author":"G Cuatrecasas","year":"2020","unstructured":"Cuatrecasas G, de Cabo F, Coves MJ et al (2020) Ultrasound measures of abdominal fat layers correlate with metabolic syndrome features in patients with obesity. Obes Sci Pract 6(6):660\u2013667. https:\/\/doi.org\/10.1002\/osp4.453","journal-title":"Obes Sci Pract"},{"issue":"4","key":"2791_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2214\/AJR.22.27656","volume":"219","author":"T Kumada","year":"2022","unstructured":"Kumada T, Toyoda H, Yasuda S et al (2022) Liver stiffness measurements by 2D shear-wave elastography: effect of steatosis on fibrosis evaluation. AJR Am J Roentgenol 219(4):604\u2013612. https:\/\/doi.org\/10.2214\/AJR.22.27656","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"2791_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1148\/radiol.2015150619","volume":"276","author":"RG Barr","year":"2015","unstructured":"Barr RG, Ferraioli G, Palmeri ML et al (2015) Elastography assessment of liver fibrosis: Society of Radiologists in Ultrasound consensus conference statement. Radiology 276(3):845\u2013861. https:\/\/doi.org\/10.1148\/radiol.2015150619","journal-title":"Radiology"},{"issue":"2","key":"2791_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1148\/radiol.2020192437","volume":"296","author":"RG Barr","year":"2020","unstructured":"Barr RG, Wilson SR, Rubens D et al (2020) Update to the Society of Radiologists in Ultrasound liver elastography consensus statement. Radiology 296(2):263\u2013274. https:\/\/doi.org\/10.1148\/radiol.2020192437","journal-title":"Radiology"},{"issue":"5","key":"2791_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KGMM Alberti","year":"2006","unstructured":"Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome\u2014a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23(5):469\u2013480. https:\/\/doi.org\/10.1111\/j.1464-5491.2006.01858.x","journal-title":"Diabet Med"},{"key":"2791_CR20","doi-asserted-by":"publisher","unstructured":"Grundy SM, Brewer HB, Cleeman JI et al (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition. Circulation. ;109(3):433\u2013438. https:\/\/doi.org\/10.1161\/01.CIR.0000111245.75752.C6","DOI":"10.1161\/01.CIR.0000111245.75752.C6"},{"issue":"1","key":"2791_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth D (1993) Bias reduction of maximum likelihood estimates. Biometrika 80(1):27\u201338. https:\/\/doi.org\/10.1093\/biomet\/80.1.27","journal-title":"Biometrika"},{"issue":"4","key":"2791_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan N, H\u00e4ring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7(4):313\u2013324. https:\/\/doi.org\/10.1016\/S2213-8587(18)30154-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2791_CR23","doi-asserted-by":"publisher","first-page":"155937","DOI":"10.1016\/j.metabol.2024.155937","volume":"157","author":"M Huttasch","year":"2024","unstructured":"Huttasch M, Roden M, Kahl S (2024) Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease? Metabolism 157:155937. https:\/\/doi.org\/10.1016\/j.metabol.2024.155937","journal-title":"Metabolism"},{"issue":"21","key":"2791_CR24","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02791-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02791-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02791-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:06:41Z","timestamp":1789027601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-026-02791-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":24,"alternative-id":["2791"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02791-5","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"18 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}